Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.67
(-6.71%)
SEK 1.67
(-6.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 131.4 Million SEK | -23.73% |
| 2022 | 172.28 Million SEK | 13.62% |
| 2021 | 151.63 Million SEK | -21.29% |
| 2020 | 192.65 Million SEK | 113.44% |
| 2019 | 90.25 Million SEK | 48.31% |
| 2018 | 60.85 Million SEK | -24.65% |
| 2017 | 80.77 Million SEK | -16.89% |
| 2016 | 97.18 Million SEK | 238.23% |
| 2015 | 28.73 Million SEK | 61.78% |
| 2014 | 17.76 Million SEK | 23.43% |
| 2013 | 14.38 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 113.92 Million SEK | -13.31% |
| 2023 Q4 | 131.4 Million SEK | -17.0% |
| 2023 Q3 | 158.32 Million SEK | 51.91% |
| 2023 FY | 131.4 Million SEK | -23.73% |
| 2023 Q1 | 134.4 Million SEK | -21.99% |
| 2023 Q2 | 104.22 Million SEK | -22.46% |
| 2022 Q1 | 132.1 Million SEK | -12.88% |
| 2022 Q4 | 172.28 Million SEK | -15.76% |
| 2022 Q2 | 107.71 Million SEK | -18.46% |
| 2022 FY | 172.28 Million SEK | 13.62% |
| 2022 Q3 | 204.51 Million SEK | 89.87% |
| 2021 FY | 151.63 Million SEK | -21.29% |
| 2021 Q2 | 165.02 Million SEK | -7.27% |
| 2021 Q3 | 154.47 Million SEK | -6.39% |
| 2021 Q1 | 177.95 Million SEK | -7.63% |
| 2021 Q4 | 151.63 Million SEK | -1.84% |
| 2020 Q2 | 212.31 Million SEK | 162.15% |
| 2020 FY | 192.65 Million SEK | 113.44% |
| 2020 Q4 | 192.65 Million SEK | -6.26% |
| 2020 Q3 | 205.52 Million SEK | -3.2% |
| 2020 Q1 | 80.98 Million SEK | -10.27% |
| 2019 Q4 | 90.26 Million SEK | -10.69% |
| 2019 FY | 90.25 Million SEK | 48.31% |
| 2019 Q1 | 111.63 Million SEK | 83.43% |
| 2019 Q2 | 108.23 Million SEK | -3.04% |
| 2019 Q3 | 101.06 Million SEK | -6.63% |
| 2018 Q2 | 70.29 Million SEK | -7.2% |
| 2018 FY | 60.85 Million SEK | -24.65% |
| 2018 Q4 | 60.86 Million SEK | -6.45% |
| 2018 Q3 | 65.05 Million SEK | -7.45% |
| 2018 Q1 | 75.74 Million SEK | -6.23% |
| 2017 FY | 80.77 Million SEK | -16.89% |
| 2017 Q1 | 92.92 Million SEK | -4.38% |
| 2017 Q4 | 80.77 Million SEK | -2.94% |
| 2017 Q3 | 83.21 Million SEK | -5.73% |
| 2017 Q2 | 88.27 Million SEK | -5.0% |
| 2016 Q4 | 97.18 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 97.18 Million SEK | 238.23% |
| 2016 Q2 | 51.81 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 28.73 Million SEK | 0.0% |
| 2015 Q3 | 28.73 Million SEK | 0.0% |
| 2015 FY | 28.73 Million SEK | 61.78% |
| 2014 FY | 17.76 Million SEK | 23.43% |
| 2013 FY | 14.38 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| NextCell Pharma AB | 81.28 Million SEK | -61.657% |
| Abliva AB (publ) | 87.49 Million SEK | -50.182% |
| Active Biotech AB (publ) | 44 Million SEK | -198.655% |
| Aptahem AB (publ) | 63.02 Million SEK | -108.502% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -10.94% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 90.615% |
| BioArctic AB (publ) | 1.18 Billion SEK | 88.921% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -111.43% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 93.086% |
| Cantargia AB (publ) | 223.71 Million SEK | 41.26% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -783.772% |
| CombiGene AB (publ) | 120.61 Million SEK | -8.951% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 82.714% |
| Fluicell AB (publ) | 9.34 Million SEK | -1306.938% |
| Genovis AB (publ.) | 288.85 Million SEK | 54.508% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 87.092% |
| Mendus AB (publ) | 755.95 Million SEK | 82.617% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 89.557% |
| LIDDS AB (publ) | 17.65 Million SEK | -644.31% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -213.182% |
| Saniona AB (publ) | 64.14 Million SEK | -104.867% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -148.01% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -110.667% |
| Xintela AB (publ) | 18.39 Million SEK | -614.368% |
| Amniotics AB (publ) | 26.08 Million SEK | -403.749% |
| Corline Biomedical AB | 100.1 Million SEK | -31.27% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -335.515% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 62.597% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 25.809% |
| Intervacc AB (publ) | 259.61 Million SEK | 49.383% |
| Kancera AB (publ) | 65.64 Million SEK | -100.186% |
| Lipum AB (publ) | 12.11 Million SEK | -985.12% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -291.072% |
| Nanologica AB (publ) | 77.42 Million SEK | -69.714% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 73.52% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 79.892% |
| AcouSort AB (publ) | 34.51 Million SEK | -280.749% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 39.454% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -66.99% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 52.857% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -555.696% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 82.828% |
| Simris Alg AB (publ) | 174.55 Million SEK | 24.717% |
| Ziccum AB (publ) | 14.97 Million SEK | -777.692% |
| SynAct Pharma AB | 228.01 Million SEK | 42.37% |
| OncoZenge AB (publ) | 20.34 Million SEK | -546.057% |
| Camurus AB (publ) | 1.9 Billion SEK | 93.112% |
| 2cureX AB (publ) | 16.62 Million SEK | -690.424% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -2062.383% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 6.536% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -505.487% |
| I-Tech AB | 152.44 Million SEK | 13.799% |
| Cyxone AB (publ) | 43.65 Million SEK | -201.015% |
| Biosergen AB | 7.2 Million SEK | -1724.858% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -391.006% |
| Alzinova AB (publ) | 123.18 Million SEK | -6.672% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 44.874% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -54.186% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1454.205% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -50.919% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -360.951% |